Caroline Palomeque
Stock Analyst at Ladenburg Thalmann & Co.
(0.10)
# 4,743
Out of 5,074 analysts
159
Total ratings
30.2%
Success rate
-11.7%
Average return
Main Sectors:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Initiated Coverage: Buy | $54 → $55 | $36.03 | +52.65% | 3 | Oct 15, 2026 | |
| ARDX Ardelyx | Reiterated: Buy | $16 | $3.20 | +400.00% | 2 | Aug 10, 2026 | |
| ATHE Alterity Therapeutics | Initiated Coverage: Buy | $10 | $2.15 | +365.12% | 1 | Jun 16, 2026 | |
| KRYS Krystal Biotech | Initiated Coverage: Buy | $154 | $320.13 | n/a | 2 | Oct 25, 2023 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $58 | $124.54 | n/a | 7 | Sep 11, 2023 | |
| ASND Ascendis Pharma | Reiterated: Buy | $166 | $242.99 | n/a | 12 | Sep 7, 2023 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $33 | $11.63 | n/a | 7 | Aug 16, 2023 | |
| AVXL Anavex Life Sciences | Reiterated: Buy | $40 | $1.36 | n/a | 24 | Aug 9, 2023 | |
| DNLI Denali Therapeutics | Reiterated: Buy | $54 | $18.66 | n/a | 14 | Aug 9, 2023 | |
| OCUL Ocular Therapeutix | Reiterated: Buy | $15 | $6.61 | n/a | 7 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $7.17 | n/a | 12 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $7.45 | n/a | 2 | Apr 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $5.49 | n/a | 5 | Apr 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.6517 | n/a | 8 | Apr 4, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.98 | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.187 | n/a | 14 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $0.776 | n/a | 13 | Mar 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 1,332p → 1,346p | 511p | n/a | 2 | Mar 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $34 | $0.2962 | n/a | 3 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $4.13 | n/a | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $1.85 | n/a | 6 | Mar 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $8 | $7.78 | n/a | 1 | Aug 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.000001 | n/a | 1 | Jun 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.0001 | n/a | 1 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $2.32 | n/a | 1 | May 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.135 | n/a | 1 | Apr 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.0005 | n/a | 1 | Mar 2, 2016 |
Harmony Biosciences Holdings
Oct 15, 2026
Initiated Coverage: Buy
Price Target: $54 → $55
Current: $36.03
Upside: +52.65%
Ardelyx
Aug 10, 2026
Reiterated: Buy
Price Target: $16
Current: $3.20
Upside: +400.00%
Alterity Therapeutics
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $2.15
Upside: +365.12%
Krystal Biotech
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $154
Current: $320.13
Upside: n/a
Halozyme Therapeutics
Sep 11, 2023
Reiterated: Buy
Price Target: $58
Current: $124.54
Upside: n/a
Ascendis Pharma
Sep 7, 2023
Reiterated: Buy
Price Target: $166
Current: $242.99
Upside: n/a
COMPASS Pathways
Aug 16, 2023
Reiterated: Buy
Price Target: $33
Current: $11.63
Upside: n/a
Anavex Life Sciences
Aug 9, 2023
Reiterated: Buy
Price Target: $40
Current: $1.36
Upside: n/a
Denali Therapeutics
Aug 9, 2023
Reiterated: Buy
Price Target: $54
Current: $18.66
Upside: n/a
Ocular Therapeutix
Aug 8, 2023
Reiterated: Buy
Price Target: $15
Current: $6.61
Upside: n/a
Aug 3, 2023
Reiterated: Buy
Price Target: $61
Current: $7.17
Upside: n/a
Apr 29, 2019
Reiterated: Buy
Price Target: $10
Current: $7.45
Upside: n/a
Apr 23, 2019
Rated: Buy
Price Target: $5
Current: $5.49
Upside: n/a
Apr 4, 2019
Reiterated: Buy
Price Target: $3
Current: $0.6517
Upside: n/a
Apr 1, 2019
Downgraded: Hold
Price Target: n/a
Current: $1.98
Upside: n/a
Apr 1, 2019
Reiterated: Buy
Price Target: $6
Current: $0.187
Upside: n/a
Mar 28, 2019
Reiterated: Buy
Price Target: $9
Current: $0.776
Upside: n/a
Mar 14, 2019
Reiterated: Buy
Price Target: 1,332p → 1,346p
Current: 511p
Upside: n/a
Mar 20, 2018
Rated: Buy
Price Target: $34
Current: $0.2962
Upside: n/a
Mar 13, 2018
Rated: Buy
Price Target: $20
Current: $4.13
Upside: n/a
Mar 9, 2018
Rated: Buy
Price Target: $9
Current: $1.85
Upside: n/a
Aug 8, 2017
Rated: Buy
Price Target: $8
Current: $7.78
Upside: n/a
Jun 13, 2017
Rated: Buy
Price Target: n/a
Current: $0.000001
Upside: n/a
Jun 7, 2017
Rated: Buy
Price Target: n/a
Current: $0.0001
Upside: n/a
May 17, 2017
Rated: Buy
Price Target: n/a
Current: $2.32
Upside: n/a
Apr 24, 2017
Rated: Buy
Price Target: n/a
Current: $0.135
Upside: n/a
Mar 2, 2016
Initiated Coverage: Buy
Price Target: $18
Current: $0.0005
Upside: n/a